5-(4-chlorophenyl)-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one | 116114-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-chlorophenyl)-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one
• 英文别名: 3H-1,2,4-Triazol-3-one, 2,4-dihydro-5-(4-chlorophenyl)-4-methyl-；3-(4-chlorophenyl)-4-methyl-1H-1,2,4-triazol-5-one
• CAS: 116114-20-6
• 化学式: C₉H₈ClN₃O
• 分子量: 209.635
• InChiKey: FMUWJXJGJZXYJN-UHFFFAOYSA-N

物化性质

• 熔点：
  213-215 °C
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(4-chlorophenyl)-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one 在 sodium hydroxide 、 双(三环己基锡(IV))硫醚 、 三氯化硼 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 41.0h， 生成 5-(4-chlorophenyl)-2,4-dihydro-2-ethyl-4-methyl-3H-1,2,4-triazole-3-thione
  参考文献：
  名称：

  The Bis(tricyclohexylstannyl) Sulfide Thionation of 3H-1,2,4- Triazol-3-ones

  摘要：

  使用双(三环己基锡)硫醚/三氯化硼组合，5-芳基-2,4-二烷基-2,4-二氢-3H-1,2,4-三唑-3-酮可以以55-74%的产率转化为相应的3H-1,2,4-三唑-3-硫酮。

  DOI：

  10.1055/s-1987-28119
• 作为产物：
  描述：

  2-(4-chlorobenzoyl)-N-methylhydrazinecarboxamide 在 sodium hydroxide 作用下， 反应 23.0h， 以69%的产率得到5-(4-chlorophenyl)-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one
  参考文献：
  名称：

  The Bis(tricyclohexylstannyl) Sulfide Thionation of 3H-1,2,4- Triazol-3-ones

  摘要：

  使用双(三环己基锡)硫醚/三氯化硼组合，5-芳基-2,4-二烷基-2,4-二氢-3H-1,2,4-三唑-3-酮可以以55-74%的产率转化为相应的3H-1,2,4-三唑-3-硫酮。

  DOI：

  10.1055/s-1987-28119

文献信息

• Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors
  申请人：Meier Heinrich

  公开号：US20090312381A1

  公开（公告）日：2009-12-17

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产方法，单独或组合使用以治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US08084481B2

  公开（公告）日：2011-12-27

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，它们的单独或组合使用用于治疗和/或预防疾病以及用于制造治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病的药物。
• SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS
  申请人：Meier Heinrich

  公开号：US20130005704A1

  公开（公告）日：2013-01-03

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新型取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，其单独或联合用于治疗和/或预防疾病的用途以及用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病。
• 2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents
  作者：John M. Kane、Bruce M. Baron、Mark W. Dudley、Stephen M. Sorensen、Michael A. Staeger、Francis P. Miller

  DOI：10.1021/jm00172a015

  日期：1990.10

  A series of 5-aryl-2,4-dihydro-3H-1,2,4-triazol-3-ones was evaluated for anticonvulsant activity. In general the members of this series were prepared by the alkaline cyclization of 1-aroyl-4-alkylsemicarbazides. The resulting 2-unsubstituted 3H-1,2,4-triazol-3-ones were then alkylated, yielding 2,4-dialkyl-3H-1,2,4-triazol-3-ones. Approximately one-third of the compounds examined exhibited activity against both maximal electroshock- and pentylenetetrazole-induced seizures in mice. Receptor-binding studies suggest that this activity was not a consequence of activity at either benzodiazepine or NMDA-type glutamate receptors. From this series, compound 45 was selected for further evaluation where it was also found to be active against 3-mercaptopropionic acid, bicuculline, and quinolinic acid induced seizures in mice. In addition, 45 also protected gerbils from hippocampal neuronal degeneration produced by either hypoxia or intrastriatal quinolinic acid injection.
• KANE, JOHN M.;BARON, BRUCE M.;DUDLEY, MARK W.;SORENSEN, STEPHEN M.;STAEGE+, J. MED. CHEM., 33,(1990) N0, C. 2772-2777
  作者：KANE, JOHN M.、BARON, BRUCE M.、DUDLEY, MARK W.、SORENSEN, STEPHEN M.、STAEGE+

  DOI：——

  日期：——